



(11) **EP 3 576 719 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 30

(51) International Patent Classification (IPC):
A61K 9/48 ^(2006.01) **A61K 9/00** ^(2006.01)
A61K 31/137 ^(2006.01) **A61K 47/10** ^(2017.01)
A61K 47/36 ^(2006.01) **A61P 25/36** ^(2006.01)

(48) Corrigendum issued on:
13.07.2022 Bulletin 2022/28

(52) Cooperative Patent Classification (CPC):
A61K 9/4866; A61K 9/0053; A61K 31/137;
A61K 47/10; A61K 47/36; A61P 25/36

(45) Date of publication and mention
of the grant of the patent:
07.07.2021 Bulletin 2021/27

(86) International application number:
PCT/US2018/017019

(21) Application number: **18706085.0**

(87) International publication number:
WO 2018/145071 (09.08.2018 Gazette 2018/32)

(22) Date of filing: **06.02.2018**

(54) **ABUSE DETERRENT FORMULATIONS OF AMPHETAMINE**

MISSBRAUCHSVERHINDERNDE FORMULIERUNGEN VON AMPHETAMIN
FORMULATIONS ANTI-ABUS D'AMPHÉTAMINE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **10.05.2017 US 201715591677**
06.02.2017 US 201762455227 P

(43) Date of publication of application:
11.12.2019 Bulletin 2019/50

(60) Divisional application:
21183311.6 / 3 943 066

(73) Proprietor: **Vallon Pharmaceuticals, Inc.**
Philadelphia, PA 19103 (US)

(72) Inventors:
• **BAKER, David**
Philadelphia, PA 19103 (US)
• **DANIELY, Yaron**
Philadelphia, PA 19103 (US)
• **RON, Hanna**
Philadelphia, PA 19103 (US)
• **SINER, David**
Philadelphia, PA 19103 (US)

(74) Representative: **Cooley (UK) LLP**
22 Bishopsgate
London EC2N 4BQ (GB)

(56) References cited:
WO-A1-2014/190440 US-A1- 2016 317 530

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).